Stay updated on Filgotinib and Lanraplenib in Female CLE Clinical Trial
Sign up to get notified when there's something new on the Filgotinib and Lanraplenib in Female CLE Clinical Trial page.

Latest updates to the Filgotinib and Lanraplenib in Female CLE Clinical Trial page
- Check4 days agoNo Change Detected
- Check12 days agoChange DetectedLakefront Biotherapeutics NV was added as a collaborator and Galapagos NV was removed from the study's Collaborators and Investigators list.SummaryDifference0.0%

- Check19 days agoChange DetectedThe page's revision tag was updated from v3.5.3 to v3.5.4, indicating a small platform update.SummaryDifference0.0%

- Check26 days agoNo Change Detected
- Check40 days agoChange DetectedThe page’s site revision/version indicator was updated from v3.5.2 to v3.5.3.SummaryDifference0.0%

- Check47 days agoChange DetectedRevision updated from v3.5.0 to v3.5.2.SummaryDifference0.0%

- Check76 days agoChange Detected- Revision: v3.5.0 has been added, replacing Revision: v3.4.3.SummaryDifference0.0%

- Check91 days agoChange DetectedRevision label updated from v3.4.2 to v3.4.3.SummaryDifference0.0%

Stay in the know with updates to Filgotinib and Lanraplenib in Female CLE Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Filgotinib and Lanraplenib in Female CLE Clinical Trial page.